Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses
The DOI matches its Crossref record.
Abstract
RATIONALE: Relatively little is known about the hepatotoxicity of pyrazinamide. OBJECTIVES: We compared continuation-phase regimens incorporating pyrazinamide, isoniazid, and/or rifampin with those containing isoniazid and rifampin to evaluate the hepatotoxicity of pyrazinamide. METHODS: Cohort and nested case-control analyses were conducted on a cohort of 3,007 patients with active tuberculosis (TB) managed at government chest clinics under a TB control program with treatment started from January 1 through June 30, 2001. Cases included all patients with probable hepatotoxicity from 12 or more weeks after starting treatment. Hepatotoxicity was considered probable when serum alanine transaminase exceeded three times the upper limit of normal. Each case was matched by sex and age with three control subjects selected randomly from the rest of the cohort. Treatment regimens of cases within 4 weeks preceding hepatotoxicity were compared with those of matched control subjects in comparable periods relative to the date of commencing treatment. MEASUREMENTS AND MAIN RESULTS: Hepatotoxicity occurred in 150 (5.0%) patients at any time including 48 (1.6%) cases. From 12 or more weeks after starting treatment, the estimated risk of hepatotoxicity was 2.6% for regimens incorporating pyrazinamide, isoniazid, and/or rifampin, and 0.8% for standard regimens containing isoniazid and rifampin. Multivariable conditional logistic analysis showed a significant association between hepatotoxicity and, respectively, hepatitis B, previous hepatotoxicity, and treatment regimens. The adjusted odds ratio (95% confidence interval) of hepatotoxicity for regimens incorporating pyrazinamide, isoniazid, and/or rifampin relative to standard regimens was 2.8 (1.4-5.9). CONCLUSIONS: Adding pyrazinamide to isoniazid and rifampin increases the risk of hepatotoxicity appreciably.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia
Conde, M. B., Melo, F. A. F. D., Marques, A. M. C., Cardoso, N. C., Pinheiro, V. G. F., Dalcin, P. D. T. R., Machado Junior, A., Lemos, A. C. M., Netto, A. R., Durovni, B., et al. (2009) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132009001000011 · Cited by 261
Caraux-Paz, P., Diamantis, S., de Wazières, B., & Gallien, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245888 · Cited by 174
Abbara, A., Chitty, S., Roe, J. K., Ghani, R., Collin, S. M., Ritchie, A., Kon, O. M., Dzvova, J., Davidson, H., Edwards, T. E., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2330-z · Cited by 100
Devarbhavi, H., Singh, R., Patil, M., Sheth, K., Adarsh, C. K., & Balaraju, G. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07279.x · Cited by 86
Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients
Gaude, G., Chaudhury, A., & Hattiholi, J. (2015) · Journal of Family Medicine and Primary Care · doi:10.4103/2249-4863.154661 · Cited by 50
Metadata
- Authors
- Chang, K. C., Leung, C. C., Yew, W. W., Lau, T. Y., & Tam, C. M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-15
- Volume
- 177
- Issue
- 12
- Pages
- 1391-1396
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2129047823
- Cited by
- 124
- References
- 0
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses. https://app.cochat.ai/papers/10.1164/rccm.200802-355oc
- The paper
- Chang, K. C., Leung, C. C., Yew, W. W., Lau, T. Y., & Tam, C. M. (2008). Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200802-355oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.